Results 131 to 140 of about 162,806 (305)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

open access: yesHaemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita   +2 more
wiley   +1 more source

PROTHROMBIN [PDF]

open access: yesJournal of Clinical Pathology, 1963
openaire   +3 more sources

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

open access: yesHaemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini   +4 more
wiley   +1 more source

Coagulation disorders after reperfusion of pancreatic allografts [PDF]

open access: yes, 1993
Blumenstock, I.   +5 more
core   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch   +8 more
wiley   +1 more source

Flow dilution effect on blood coagulation in vivo [PDF]

open access: yes
Enzyme reaction model of flow dilution effect on blood coagulation in ...
Hu, C.
core   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima   +8 more
wiley   +1 more source

Thrombosis and risk factors

open access: yesTurkish Journal of Hematology, 2010
Nejat Akar
doaj   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

open access: yesHepatology Research, EarlyView.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano   +22 more
wiley   +1 more source

Use of andexanet alfa: A British Society for Haematology position statement

open access: yes
British Journal of Haematology, EarlyView.
Richard J. Buka   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy